#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13696	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2207	617.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1725	1725	T	772	T,C	704,6	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13696	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2207	617.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1459	1459	C	794	C	744	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13696	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2207	617.2	0	HET	.	.	.	A800G	.	800	800	A	1075	1075	A	804	A,G	587,179	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13696	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2207	617.2	0	HET	.	.	.	C305T,A	.	305	305	C	580	580	C	742	C,T,A	539,156,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25666	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3669	697.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1668	1668	A	813	A,G,T	751,13,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25666	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3669	697.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2302	2302	C	788	C	733	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25666	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3669	697.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2376	2376	A	813	A	777	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25666	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3669	697.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2928	2928	C	794	C	752	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1968	folP	855	855	100.0	folP.l15.c4.ctg.1	1426	137.0	1	SNP	p	R229S	1	.	.	685	687	AGC	939	941	AGC	200;201;202	A;G;C	190;191;191	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5562	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3477	159.5	1	SNP	p	S91F	1	.	.	271	273	TTC	599	601	TTC	164;166;167	T;T,C;C	154;155,1;157	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5562	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3477	159.5	1	SNP	p	D95G	1	.	.	283	285	GGC	611	613	GGC	168;165;164	G;G,A;C	159;155,1;154	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5562	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3477	159.5	1	SNP	p	G95N	0	.	.	283	285	GGC	611	613	GGC	168;165;164	G;G,A;C	159;155,1;154	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1670	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1355	122.8	1	SNP	p	G45D	0	.	.	133	135	GGC	466	468	GGC	192;194;194	G;G;C	177;179;182	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	806	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	958	83.3	0	.	n	.	0	A197.	DEL	197	197	A	537	537	A	168	A	160	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4808	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2887	166.1	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1440	1442	GTC	190;188;192	G;T;C	182;174;181	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4808	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2887	166.1	1	SNP	p	D86N	0	.	.	256	258	GAC	546	548	GAC	188;188;187	G;A;C	176;172;176	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4808	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2887	166.1	1	SNP	p	R87I	0	.	.	259	261	CGT	549	551	CGT	188;192;193	C;G;T,C,A	176;178;178,1,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4808	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2887	166.1	1	SNP	p	R87W	0	.	.	259	261	CGT	549	551	CGT	188;192;193	C;G;T,C,A	176;178;178,1,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4808	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2887	166.1	1	SNP	p	S87R	1	.	.	259	261	CGT	549	551	CGT	188;192;193	C;G;T,C,A	176;178;178,1,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4808	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2887	166.1	1	SNP	p	S88P	0	.	.	262	264	TCC	552	554	TCC	194;196;196	T;C;C,A	179;184;184,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4188	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2668	156.3	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1398	1400	TGC	180;179;182	T,C;G;C	171,1;172;175	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4188	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2668	156.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1608	1610	GGC	187;184;183	G;G;C	176;177;174	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1190	1192	GCA	207;209;212	G;C;A	194;196;203	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1193	1195	ATC	211;212;213	A;T;C	200;202;202	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1205	1207	GTG	211;211;213	G;T;G	202;196;201	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1205	1207	GTG	211;211;213	G;T;G	202;196;201	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1709	1711	ACC	191;193;193	A;C;C	169;179;178	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1763	1765	GCG	180;176;175	G;C;G	153;137;151	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1763	1765	GCG	180;176;175	G;C;G	153;137;151	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1886	1888	GGC	159;158;160	G;G;C,T	151;147;143,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1895	1897	GGC	149;149;146	G,A;G;C	134,1;133;129	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3830	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2298	165.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1913	1915	CCG	143;145;147	C,G;C;G	111,6;115;117	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5404	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3068	175.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1637	1639	CCG	188;188;189	C;C;G,A	168;175;170,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2326	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1869	123.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	546	546	C	178	C	162	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	61	63	TTA	51;54;54	T,G;T;A	42,1;46;46	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	106	108	CAT	61;60;57	C,G;A;T	57,1;58;55	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	109	111	AGT	57;57;57	A,G;G,A;T	53,1;54,1;55	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	118	120	TAC	59;59;60	T,C;A;C	56,1;57;57	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	R307A	NONSYN	919	921	AGA	208	210	GCA	20;20;20	G;C;A	19;19;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	T311A	NONSYN	931	933	ACA	220	222	GCA	17;17;18	G;C;A	17;17;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	E312D	NONSYN	934	936	GAA	223	225	GAC	19;18;18	G;A;C	17;16;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	F314I	NONSYN	940	942	TTC	229	231	ATC	19;19;19	A;T;C	18;18;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	A316S	NONSYN	946	948	GCG	235	237	TCG	19;19;19	T;C;G	18;19;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	V318A	NONSYN	952	954	GTC	241	243	GCC	20;20;19	G;C;C	19;20;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	G319S	NONSYN	955	957	GGC	244	246	AGC	19;19;19	A;G;C	16;19;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	G320A	NONSYN	958	960	GGT	247	249	GCC	18;18;18	G;C;C	17;18;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	288	porB1a	984	271	91.51	porB1a.l15.c30.ctg.1	310	37.7	0	.	p	.	0	G322V	NONSYN	964	966	GGT	253	255	GTT	18;18;17	G;T;T	16;18;16	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	378	380	GAA	182;182;179	G;A;A	172;172;167	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	666	668	GAT	196;196;194	G,A;A;T	187,3;189;187	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	789	791	TCA	247;246;247	T;C;A	236;233;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	918	920	GTC	205;206;206	G;T;C,T	196;197;196,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1248	1250	GCA	191;192;193	G;C,A;A	176;177,1;180	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	1	SNP	p	G120K	1	.	.	358	360	AAG	624	626	AAG	200;199;200	A;A;G	193;190;189	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	1	SNP	p	A121D	1	.	.	361	363	GAC	627	629	GAC	201;203;201	G,A;A;C	189,1;188;192	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2498	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1594	155.9	1	SNP	p	D121N	0	.	.	361	363	GAC	627	629	GAC	201;203;201	G,A;A;C	189,1;188;192	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9614	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4985	192.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2043	2045	AAT	216;217;217	A,C;A;T	203,4;210;207	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1104	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1077	101.8	1	SNP	p	V57M	1	.	.	169	171	ATG	480	482	ATG	217;217;215	A;T;G	203;200;199	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
